Hi there,

If you think Democracy Now!’s reporting is a critical line of defense against war, climate catastrophe and authoritarianism, please make your donation of $10 or more right now. Today, a generous donor will DOUBLE your donation, which means it’ll go 2x as far to support our independent journalism. Democracy Now! is funded by you, and that’s why we’re counting on your donation to keep us going strong. Please give today. Every dollar makes a difference—in fact, gets doubled! Thank you so much.
-Amy Goodman

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.

Donate

Federal Company Vaccine Mandate Reinstated; New Data Show Moderna Booster Helps Fight Omicron

HeadlineDec 20, 2021

COVID-19 surges have been reported in more countries as the Omicron variant continues its rapid spread. Here in the U.S., an average of 1,300 people are still dying every day, with Delta remaining the dominant variant for now. Across the country, long lines formed at testing sites amid a wave of new infections and as people prepare for holiday travel and gatherings. Meanwhile, a federal appeals court Friday reinstated the Biden administration vaccine-or-testing mandate for companies with 100 or more employees.

In medical news, Moderna said lab tests showed its booster increases the level of Omicron-fighting antibodies by around 37-fold. Health officials are asking vaccinated people to get boosted as soon as possible in hopes of curbing the winter surge. This is Dr. Anthony Fauci.

Dr. Anthony Fauci: “We are going to see breakthrough infections, Chuck. There’s no doubt about that. The difference between a vaccinated and boosted person who has an infection and someone who has an infection who’s never been vaccinated, a major difference with regard to the risk of severity.”

In other medical news, Pfizer said Friday its vaccine trials on 2-to-4-year-olds generated a weaker immune response than expected. Pfizer is now expanding its clinical trials to see if a third dose will produce a robust immune response in young children — with results not expected for months.

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to democracynow.org. Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.
Make a donation
Top